Experienced in Diffuse Large B-Cell Lymphoma (DLBCL)

Marion J. Hommel-Kuper

Hamilton, WKO, NZ 
Experienced in Diffuse Large B-Cell Lymphoma (DLBCL)
Hamilton, WKO, NZ 
OverviewLocationsClinical Research

Overview

Marion Hommel-Kuper practices in Hamilton, New Zealand. Hommel-Kuper is rated as an Experienced expert by MediFind in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). Their top areas of expertise are Breast Cancer, B-Cell Lymphoma, Non-Hodgkin Lymphoma, and Sialadenitis.

Their clinical research consists of co-authoring 33 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 2 articles in the study of Diffuse Large B-Cell Lymphoma (DLBCL).

Locations

Hamilton, WKO, New Zealand
Other Locations
261 Morrin Road, Private Bag 92019, Auckland, AUK 1142, New Zealand
WKO, New Zealand

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
Phase II, Randomised, Double-blinded, Placebo Controlled, Crossover Trial to Assess Pantoprazole's Effectiveness as Prophylaxis Against Delayed CINV in Patients Receiving Adjuvant or Neoadjuvant Breast Cancer Chemotherapy
Phase II, Randomised, Double-blinded, Placebo Controlled, Crossover Trial to Assess Pantoprazole's Effectiveness as Prophylaxis Against Delayed CINV in Patients Receiving Adjuvant or Neoadjuvant Breast Cancer Chemotherapy
Enrollment Status: Completed
Publish Date: May 25, 2022
Intervention Type: Drug
Study Drug: Pantoprazole
Study Phase: Phase 2
View 1 Less Clinical Trial

33 Total Publications

Differences in systemic treatments for breast cancer between patients with and without diabetes.
Differences in systemic treatments for breast cancer between patients with and without diabetes.
Journal: The New Zealand medical journal
Published: April 10, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Hommel-Kuper's expertise for a condition
ConditionClose
      View All 8 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile